PEGylated Antibody Drug Conjugate Linker Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibody-drug conjugates face challenges in maintaining the stability and improving the physical properties of the drug, leading to variable therapeutic effects.
Innovation Solution
A novel antibody-drug conjugate is developed, incorporating a specific linker unit that includes polyethylene glycol (PEG) units, which enhances stability and prevents hydrophobic drug precipitation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If PEGylation is performed in existing antibody-drug conjugates, then plasma half-life is extended and stability is improved, but drug properties are not improved in all cases and therapeutic effects vary
Solution Approach 1:
The patent introduces a specific PEG linker structure with defined parameters (z=1-20, n=1-20, m=1-20) where at least one of X1, X2, or X3 is a polyethylene glycol unit. This localized optimization of the linker region with controlled PEG integration provides consistent therapeutic effects while maintaining stability, resolving the variability issue of conventional PEGylation approaches.
Solution Approach 2:
The patent systematically varies and optimizes multiple parameters including the PEG unit structure (X1, X2, X3), repetition numbers (z, n, m), and linker configuration to achieve both enhanced stability and consistent therapeutic effects. This parameter optimization approach transforms the unreliable variable effects into predictable, consistent outcomes.
2Reliability
If hydrophobic drugs are used in antibody-drug conjugates, then pharmacological effect is enhanced, but drug precipitation occurs reducing delivery efficiency
Solution Approach 1:
The patent uses the PEG-containing linker as an intermediary between the hydrophobic drug and the aqueous environment. The PEG units provide hydrophilic character that mediates the solubility issue, allowing hydrophobic drugs to be delivered efficiently without precipitation while maintaining their pharmacological activity.
Solution Approach 2:
The patent creates a composite linker structure combining hydrophobic and hydrophilic components, where the PEG units provide water solubility while the linker maintains drug binding capability. This composite approach resolves the contradiction between hydrophobic drug potency and aqueous solubility for efficient delivery.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel antibody-drug conjugate exhibits improved stability and physical properties, leading to increased drug delivery efficiency and enhanced therapeutic effects.
Implementation Method 1
Polyethylene glycol (PEG) is a water-soluble, biocompatible and nontoxic polymer... used in the pharmaceutical field to extend plasma half-life, prevent enzymatic degradation, and provide sustained release through PEGylation
Data Source
AI summary
The present invention relates to a novel antibody drug conjugate and, specifically, to an antibody drug conjugate comprising polyethylene glycol, a solvate thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing the same, wherein the conjugate has excellent physical properties and stability.